HRP20110434T1 - Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 - Google Patents
Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 Download PDFInfo
- Publication number
- HRP20110434T1 HRP20110434T1 HR20110434T HRP20110434T HRP20110434T1 HR P20110434 T1 HRP20110434 T1 HR P20110434T1 HR 20110434 T HR20110434 T HR 20110434T HR P20110434 T HRP20110434 T HR P20110434T HR P20110434 T1 HRP20110434 T1 HR P20110434T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- amino
- pyrazolo
- pyridin
- diethyl
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- DEPWAGNOLISJQB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 DEPWAGNOLISJQB-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims abstract 4
- 208000026935 allergic disease Diseases 0.000 claims abstract 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 2
- 230000000172 allergic effect Effects 0.000 claims abstract 2
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims abstract 2
- 206010039083 rhinitis Diseases 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- -1 C1-2fluoroalkyl Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 101100006941 Caenorhabditis elegans sex-1 gene Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- BGGGGSRXEVBHTI-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide;hydrochloride Chemical compound Cl.C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 BGGGGSRXEVBHTI-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- PHCXFLVZSJXLCQ-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-(4-morpholin-4-ylbutoxy)butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PHCXFLVZSJXLCQ-UHFFFAOYSA-N 0.000 claims 1
- UVOMAWFRWZVSRS-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-(4-pyrrolidin-1-ylbutoxy)butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 UVOMAWFRWZVSRS-UHFFFAOYSA-N 0.000 claims 1
- LQXPAXAIHLXYGQ-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-[4-[2-hydroxyethyl(methyl)amino]butoxy]butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 LQXPAXAIHLXYGQ-UHFFFAOYSA-N 0.000 claims 1
- PCOQMMAGXDJXFT-SSEXGKCCSA-N 4-[[1,6-diethyl-5-[[[4-[8-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PCOQMMAGXDJXFT-SSEXGKCCSA-N 0.000 claims 1
- PCOQMMAGXDJXFT-PMERELPUSA-N 4-[[1,6-diethyl-5-[[[4-[8-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PCOQMMAGXDJXFT-PMERELPUSA-N 0.000 claims 1
- SPESJTHXLGHPOW-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 SPESJTHXLGHPOW-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 229910005965 SO 2 Inorganic materials 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- QGZWUSODSJBHDB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=CC=C(NC(=O)CCCCCCCN(C)CCO)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 QGZWUSODSJBHDB-UHFFFAOYSA-N 0.000 claims 1
- JIHFKHSXPSMWSO-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=CC(NC(=O)CCCCCCCN(C)CCO)=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 JIHFKHSXPSMWSO-UHFFFAOYSA-N 0.000 claims 1
- UWBGOPUYNYLDRM-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-morpholin-4-yloctanoylamino)benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 UWBGOPUYNYLDRM-UHFFFAOYSA-N 0.000 claims 1
- BEPDHRGYGYZEND-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-morpholin-4-yloctyl)benzamide Chemical compound C=1C=C(CCCCCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 BEPDHRGYGYZEND-UHFFFAOYSA-N 0.000 claims 1
- LTPXTKORBUECMF-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-pyrrolidin-1-yloctanoylamino)benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 LTPXTKORBUECMF-UHFFFAOYSA-N 0.000 claims 1
- YDCZHFGZHRPCBD-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[10-[2-hydroxyethyl(methyl)amino]decanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 YDCZHFGZHRPCBD-UHFFFAOYSA-N 0.000 claims 1
- ZRFLKCUWKNHLBE-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[11-[2-hydroxyethyl(methyl)amino]undecanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ZRFLKCUWKNHLBE-UHFFFAOYSA-N 0.000 claims 1
- HNZYCJSOXTZPFW-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-(4-morpholin-4-ylbutoxy)butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HNZYCJSOXTZPFW-UHFFFAOYSA-N 0.000 claims 1
- HOKINZWWJXHPBQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-(4-pyrrolidin-1-ylbutoxy)butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HOKINZWWJXHPBQ-UHFFFAOYSA-N 0.000 claims 1
- VJPSYBYOJJNRCL-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-[4-[2-hydroxyethyl(methyl)amino]butoxy]butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 VJPSYBYOJJNRCL-UHFFFAOYSA-N 0.000 claims 1
- HWXCFWXSIMAGRN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[6-[2-hydroxyethyl(methyl)amino]hexanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HWXCFWXSIMAGRN-UHFFFAOYSA-N 0.000 claims 1
- WNZVGXGWURJHEN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[7-[2-hydroxyethyl(methyl)amino]heptanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 WNZVGXGWURJHEN-UHFFFAOYSA-N 0.000 claims 1
- MDKFYYZQPFHXSN-SSEXGKCCSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MDKFYYZQPFHXSN-SSEXGKCCSA-N 0.000 claims 1
- MDKFYYZQPFHXSN-PMERELPUSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MDKFYYZQPFHXSN-PMERELPUSA-N 0.000 claims 1
- SWOQFOQBQPKIBC-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octyl]benzamide Chemical compound C=1C=C(CCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 SWOQFOQBQPKIBC-UHFFFAOYSA-N 0.000 claims 1
- FYSISNCELBVBIX-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 FYSISNCELBVBIX-UHFFFAOYSA-N 0.000 claims 1
- XMANGTFEUXAABH-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 XMANGTFEUXAABH-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0615286A GB0615286D0 (en) | 2006-08-01 | 2006-08-01 | Compounds |
| GB0706790A GB0706790D0 (en) | 2007-04-05 | 2007-04-05 | Compounds |
| GB0714815A GB0714815D0 (en) | 2007-07-30 | 2007-07-30 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors |
| PCT/GB2007/002908 WO2008015416A1 (en) | 2006-08-01 | 2007-07-31 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110434T1 true HRP20110434T1 (hr) | 2011-08-31 |
Family
ID=38996907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110434T HRP20110434T1 (hr) | 2006-08-01 | 2011-06-09 | Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20090325952A1 (de) |
| EP (1) | EP2046787B1 (de) |
| JP (1) | JP2009545579A (de) |
| AT (1) | ATE504586T1 (de) |
| AU (1) | AU2007280214A1 (de) |
| CA (1) | CA2659539A1 (de) |
| CL (1) | CL2007002349A1 (de) |
| CY (1) | CY1111625T1 (de) |
| DE (1) | DE602007013762D1 (de) |
| DK (1) | DK2046787T3 (de) |
| HK (1) | HK1127603A1 (de) |
| HR (1) | HRP20110434T1 (de) |
| NZ (1) | NZ574533A (de) |
| PL (1) | PL2046787T3 (de) |
| PT (1) | PT2046787E (de) |
| SI (1) | SI2046787T1 (de) |
| TW (1) | TW200840818A (de) |
| WO (2) | WO2008015416A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2659539A1 (en) * | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| US8784847B2 (en) * | 2009-04-17 | 2014-07-22 | Merz Pharma Gmbh & Co. Kgaa | Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate |
| US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
| CA2808660A1 (en) * | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| EP2628730B1 (de) * | 2012-02-16 | 2017-12-06 | Noxell Corporation | Mehrstufige eintopfsynthese von salzen des 5-amino-4-nitroso-1-alkyl-1h-pyrazols |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| DE102015000626A1 (de) * | 2015-01-22 | 2016-07-28 | Kibion Gmbh | Verfahren zum Nachweis von Helicobacter Pylori |
| CN111732543A (zh) * | 2020-08-14 | 2020-10-02 | 浙江鼎龙科技有限公司 | 一种4,5-二氨基-1-（2-羟乙基）吡唑硫酸盐的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3200123A (en) * | 1962-01-26 | 1965-08-10 | Richardson Merreil Inc | Imidazoquinolines |
| JPS4824396B1 (de) | 1970-09-09 | 1973-07-20 | ||
| CA1201114A (en) | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
| DE3927761C2 (de) | 1989-08-23 | 1997-11-27 | Huels Chemische Werke Ag | Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP1281770B1 (de) | 1993-03-10 | 2010-03-03 | GlaxoSmithKline LLC | Phosphodiesterase des menschlichen Gehirns und Screening-Verfahren |
| ES2122261T3 (es) | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester. |
| NZ289157A (en) | 1994-06-15 | 1998-03-25 | Wellcome Found | Amidino sulphoxides and sulphones; medicaments for selective inhibition of inducible nitric oxide synthase |
| EP0832069B1 (de) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion |
| CZ416498A3 (cs) | 1996-06-17 | 1999-06-16 | Smithkline Beecham Plc | Substituovaný benzamidový derivát a jeho použití jako antikonvulsantu |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| IL131756A0 (en) | 1997-03-18 | 2001-03-19 | Smithkline Beecham Plc | Substituted isoquinoline derivatives and their use as anticonvulsants |
| AUPO622597A0 (en) | 1997-04-15 | 1997-05-08 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| JPH11174621A (ja) | 1997-10-08 | 1999-07-02 | Fuji Photo Film Co Ltd | 熱現像写真感光材料 |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| CZ303154B6 (cs) | 1998-11-13 | 2012-05-09 | Jagotec Ag | Suchá prášková formulace k inhalaci obsahující stearát horecnatý |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| ATE306481T1 (de) | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| EP1301484A2 (de) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin-rezeptor-liganden |
| AR032471A1 (es) | 2000-08-05 | 2003-11-12 | Glaxo Group Ltd | Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| KR100912324B1 (ko) | 2001-09-14 | 2009-08-14 | 글락소 그룹 리미티드 | 호흡기 질환 치료용 펜에탄올아민 유도체 |
| GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| GB0208608D0 (en) | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Composition |
| US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| NZ538515A (en) | 2002-09-16 | 2007-04-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| SI1556342T1 (sl) | 2002-10-28 | 2008-08-31 | Glaxo Group Ltd | Fenetanolaminski derivat za zdravljenje respiratornih bolezni |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| AR046103A1 (es) | 2003-10-14 | 2005-11-23 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
| JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
| AR046225A1 (es) | 2003-11-04 | 2005-11-30 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion |
| US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
| GB0405937D0 (en) * | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| US7709497B2 (en) | 2004-03-16 | 2010-05-04 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor |
| UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| WO2007036734A1 (en) | 2005-09-29 | 2007-04-05 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
| CA2659539A1 (en) * | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
-
2007
- 2007-07-31 CA CA002659539A patent/CA2659539A1/en not_active Abandoned
- 2007-07-31 JP JP2009522327A patent/JP2009545579A/ja active Pending
- 2007-07-31 US US12/375,685 patent/US20090325952A1/en not_active Abandoned
- 2007-07-31 AT AT07766400T patent/ATE504586T1/de active
- 2007-07-31 PL PL07766400T patent/PL2046787T3/pl unknown
- 2007-07-31 US US11/831,325 patent/US8003663B2/en not_active Expired - Fee Related
- 2007-07-31 DK DK07766400.1T patent/DK2046787T3/da active
- 2007-07-31 SI SI200730620T patent/SI2046787T1/sl unknown
- 2007-07-31 AU AU2007280214A patent/AU2007280214A1/en not_active Abandoned
- 2007-07-31 NZ NZ574533A patent/NZ574533A/en not_active IP Right Cessation
- 2007-07-31 EP EP07766400A patent/EP2046787B1/de active Active
- 2007-07-31 PT PT07766400T patent/PT2046787E/pt unknown
- 2007-07-31 WO PCT/GB2007/002908 patent/WO2008015416A1/en active Application Filing
- 2007-07-31 DE DE602007013762T patent/DE602007013762D1/de active Active
- 2007-08-01 US US12/375,695 patent/US20090318494A1/en not_active Abandoned
- 2007-08-01 WO PCT/GB2007/002935 patent/WO2008015437A1/en active Application Filing
- 2007-08-13 CL CL200702349A patent/CL2007002349A1/es unknown
- 2007-08-22 TW TW096131112A patent/TW200840818A/zh unknown
-
2009
- 2009-07-22 HK HK09106718.9A patent/HK1127603A1/xx not_active IP Right Cessation
-
2011
- 2011-06-09 HR HR20110434T patent/HRP20110434T1/hr unknown
- 2011-06-28 CY CY20111100623T patent/CY1111625T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2046787T3 (pl) | 2011-10-31 |
| CY1111625T1 (el) | 2015-10-07 |
| US20090325952A1 (en) | 2009-12-31 |
| DE602007013762D1 (de) | 2011-05-19 |
| CA2659539A1 (en) | 2008-02-07 |
| JP2009545579A (ja) | 2009-12-24 |
| AU2007280214A1 (en) | 2008-02-07 |
| EP2046787A1 (de) | 2009-04-15 |
| US20090318494A1 (en) | 2009-12-24 |
| US20080058369A1 (en) | 2008-03-06 |
| NZ574533A (en) | 2011-05-27 |
| WO2008015416A1 (en) | 2008-02-07 |
| ATE504586T1 (de) | 2011-04-15 |
| DK2046787T3 (da) | 2011-07-18 |
| PT2046787E (pt) | 2011-06-15 |
| EP2046787B1 (de) | 2011-04-06 |
| WO2008015437A1 (en) | 2008-02-07 |
| CL2007002349A1 (es) | 2008-10-10 |
| TW200840818A (en) | 2008-10-16 |
| HK1127603A1 (en) | 2009-10-02 |
| SI2046787T1 (sl) | 2011-07-29 |
| US8003663B2 (en) | 2011-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110434T1 (hr) | Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 | |
| JP2014037426A5 (de) | ||
| JP5169829B2 (ja) | へテロ環ヤヌスキナーゼ３阻害剤 | |
| ES2776654T3 (es) | Composición farmacéutica para administración oral que comprende un modulador de P2X7 | |
| JP6684552B2 (ja) | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン | |
| WO2004024728A3 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| JP2017511365A5 (de) | ||
| HRP20170896T1 (hr) | Derivati pirimidina | |
| NZ587039A (en) | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| RU2015127079A (ru) | Соединения, используемые в качестве ингибиторов киназы atr | |
| TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| CA2565852A1 (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| JP2014531458A5 (de) | ||
| RU2014106020A (ru) | Ингибиторы втк | |
| EA200970852A1 (ru) | Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| JP2013500247A5 (de) | ||
| JP2017515848A5 (de) | ||
| RU2014131367A (ru) | Соединения тиенопиримидина | |
| TW202411229A (zh) | 用於治療發炎性病症之新穎化合物及其醫藥組合物 | |
| WO2021032582A1 (en) | Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2009532413A5 (de) | ||
| JP2023533849A (ja) | Ａｌｋ５阻害剤としてのピリダジニルアミノ誘導体 |